BRNS - CIK 0001828185
Barinthus Biotherapeutics plc. trades as BRNS. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$66.43M. This page tracks Barinthus Biotherapeutics plc. through 247 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -367.3% to -408.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| New insider ownership | 3 | 2026-05-01 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| DEFM14A | - | 2026-04-30 |
| Major company event | 8-K | 2026-04-22 |
| SCHEDULE 13D | - | 2026-04-13 |
| Major company event | 8-K | 2026-03-31 |
The largest companies sharing Barinthus Biotherapeutics plc.'s SEC industry classification (pharmaceutical preparations).
Barinthus Biotherapeutics plc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Barinthus Biotherapeutics plc. reported a net loss of $66.43M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.